Here are the top 5 most-viewed alopecia content in 2025.

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

Absci Corporation (NASDAQ:ABSI) is one of the best multibagger penny stocks to buy right now. On December 12, Needham’s Gil ...

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...

Nektar Therapeutics may have a pipeline-in-a-drug with rezpegaldesleukin, has additional readouts ahead, and cash until 2027.

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...

Dr. Hordinsky discusses how clascoterone 5% topical solution may reshape male AGA management and expand treatment confidence.

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.